Epigenomics

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Retrieved on: 
Monday, October 16, 2023
HIV disease progression rates, NSCLC, AACR, Cancer, EGFR, Lung cancer, Therapy, Biopsy, Messenger, Conference, Epigenomics, Patient, MYC, Pharmaceutical industry

“These new data build on our previous results demonstrating anti-tumor activity of OTX-2101 as a monotherapy in preclinical NSCLC models and highlight its potential ability to synergize with clinically validated strategies.

Key Points: 
  • “These new data build on our previous results demonstrating anti-tumor activity of OTX-2101 as a monotherapy in preclinical NSCLC models and highlight its potential ability to synergize with clinically validated strategies.
  • Combination of a MYC-targeting epigenomic controller (MYC-EC) with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity.
  • Treatment with a MYC-EC plus an anti-PD-L1 antibody resulted in enhanced anti-tumor activity in a syngeneic mouse model of NSCLC.
  • Combination of MYC-EC with EGFR inhibitor, osimertinib, synergistically reduced tumor cell viability in vitro and significantly inhibited tumor growth in vivo in a human xenograft model of NSCLC.

EQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023

Retrieved on: 
Tuesday, October 17, 2023
News, USD, EBITDA, Supervisory board, AG, Epigenomics AG, RTÉ Executive Board, Patient, Sale, Epigenomics, Security (finance), Bank, Rare-earth element

As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.

Key Points: 
  • As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.
  • As part of the closing, the Company has received as consideration a cash payment of USD 0.5 million and an interest in New Day Diagnostics.
  • Jens Ravens, Executive of Epigenomics AG: “The transfer of almost all assets now completed represents the closing of the sale which was overwhelmingly approved by our Extraordinary General Meeting on September 11, 2023.
  • The adjustment results essentially from the income for the year 2023 from the contract with New Day Diagnostics.

Gustavo Grodnitzky PhD: How to Reimagine the Medical Culture and Reduce Burnout by Gaining a Creative Perspective with Yoga Science

Retrieved on: 
Tuesday, October 3, 2023
Critical Care Medicine (journal), Heart, Doctor of Philosophy, Science, American Medical Association, MD, Patient, Faculty, University, Diet, Culture, Himalayan Institute of Yoga Science and Philosophy, Research, Brain, American Meditation Institute, Family medicine, Addiction medicine, Population health, AMI, Conference, Exercise, Neurochemistry, Curriculum, Ayurveda, Holism, Creativity, Forensic psychology, Hofstra University, Burnout, CME, Speech, Inflammation, Student, Mevalonate pathway, Physician, Internal medicine, Meditation, Health, Chronic pain, Medical education, Food, Nursing, Pediatrics, Yoga, Epigenomics, Medicine

AVERILL PARK, N.Y., Oct. 3, 2023 /PRNewswire-PRWeb/ -- Gustavo Grodnitzky PhD will join the faculty of the American Meditation Institute (AMI) during the 12th annual Heart and Science of Yoga Conference, October 17-21, 2023 at the Equinox Resort and Spa in Manchester, Vermont. Accredited for 32 CMEs, (34 for conference alumni), this comprehensive training in Yoga Science as Holistic Mind/Body Medicine is accredited through the American Medical Association, and designed to help identify, prevent and relieve the burnout and stress currently being experienced by physicians and other healthcare professionals.

Key Points: 
  • Gustavo Grodnitzky PhD
    Dr. Grodnitzky is a noted psychologist, speaker, author and consultant, and serves as Chair of the AMI Department of Psychological Education.
  • Grodnitzky's participation at this year's CME conference will include practical, thought-provoking insights into how the power of culture currently restricts physicians' perspective and resilience.
  • Demonstrate knowledge of how Yoga Science as mind/body medicine can heal disease, manage addictive habits, alleviate stress, inflammation and physician burnout; 2.
  • Use the tools of Yoga Science to create a personal and medical culture of health and wellbeing.

Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics

Retrieved on: 
Wednesday, September 20, 2023
Other Health, Health, Technology, Artificial Intelligence, Cardiology, Exercise, DNA, Radiation, Epigenomics, Moyamoya disease, Personalized medicine, CT pulmonary angiogram, MD, Investment, Manuscript, Patient, Risk, Nested polymerase chain reaction, Artificial intelligence, Diagnosis, AI, SATRO-ECG, Death, CHD, PCR, Medical device, Research

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause of death worldwide in the journal Epigenomics.

Key Points: 
  • Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause of death worldwide in the journal Epigenomics.
  • This review lays out an affordable, scalable framework to use artificial intelligence-guided epigenetic assessments for CHD risk assessment, diagnosis, and management.
  • The digital PCR-based approach requires only minimal infrastructure investments while providing unparalleled personalized biological insights into the drivers of each patient's CHD presentation.
  • "Our research shows a clear pathway for precision epigenetics to fill critical unmet needs in cardiac care on a national and global scale," said Dr. Robert Philibert, Chief Medical Officer and Co-Founder of Cardio Diagnostics.

Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs

Retrieved on: 
Tuesday, September 12, 2023
Proteogenomics, Population health, Epigenomics, HT, Genomics, Research, Proteomics, Protein, Gene, Disease, Vaccine

UPPSALA, Sweden, 12th September, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology.

Key Points: 
  • The Olink platform represents the cutting edge in proteomics technology, delivering exceptional sensitivity and specificity for protein biomarker measurement.
  • Eurofins Genomics joins a worldwide network of service providers that have adopted the Olink platform.
  • Eurofins Genomics is a recognized leader in providing multi-omics services covering genomics, transcriptomics, and epigenomics.
  • Now, with the addition of Olink technology, Eurofins Genomics will offer the most powerful proteomic technology available for a more thorough understanding of the intricate connections between genes, proteins, and diseases.

New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting

Retrieved on: 
Thursday, September 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Extraordinary general meeting, Epigenomics AG, Cancer, Sale, Organization, Estate (law), Acquisition, Aktiengesellschaft, Patient, Colorectal cancer, Epigenomics, Medical device, Medical imaging

New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.

Key Points: 
  • New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.
  • The agreement's completion will further enhance New Day Diagnostics' ability to improve lives by empowering people with innovative, accessible diagnostics.
  • “New Day Diagnostics is thrilled that the resolutions required for the execution of this Agreement have been successfully passed,” said Eric Mayer, President and CEO of New Day Diagnostics.
  • Additionally, the Extraordinary General Meeting gave the green light to amend the statutory purpose of Epigenomics AG, aligning it with the future purpose of Epigenomics AG and the strategic goals of the acquisition.

EQS-News: Epigenomics AG: Pareto and Warburg publish analyst research reports

Retrieved on: 
Tuesday, September 5, 2023
Warburg, Epigenomics AG, Supervisory board, Research, Sale, EUR, RTÉ Executive Board, Hold, Southwestern Advantage, Pareto, Cryptocurrency, Epigenomics

Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.

Key Points: 
  • Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.
  • Both analysts consider the sale of substantial assets to New Day Diagnostics LLC as a chance to realize the potential and value of Epigenomics' blood-based colorectal cancer test Epi proColon “Next-Gen”.
  • With the shift from "Hold" to "Buy", Warburg even indicates that they consider the sale of significant assets likely to be more advantageous for shareholders than a further independent development.
  • Pareto and Warburg set the price target at EUR 3.15 and EUR 3.30, respectively, subject to approval by Epigenomics AG's shareholders at the Extraordinary General Shareholders' Meeting on September 11, 2023, in Berlin.

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023
General Health, Health, Oncology, Glioma, Molecular biology, BioNTech, KRAS, Huangshan, Translation, Broad Institute, Drug development, Biochemistry, Epigenomics, Cone Health Women's Hospital, CSO, Mirati Therapeutics, Chicago Medical School, Cancer, Drug, Clinical Cancer Research, Lung cancer, Rosalind Franklin University of Medicine and Science, MIT, Boston University, Harvard University, Harvard Medical School, Neuro, Managing editor, Mirati, Neurology, Hospital, Research, FDA, Massachusetts General Hospital, Therapy, Neon, Dana–Farber Cancer Institute, Pharmaceutical industry, Science

Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.

Key Points: 
  • Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
  • “We are excited to welcome Andrew to Alterome during this important phase as we advance our first two programs into the clinic next year,” said Eric Murphy, Ph.D., co-founder, CEO and CSO of Alterome Therapeutics.
  • “Andrew is a talented physician-scientist who brings considerable expertise across all stages of oncology drug development spanning clinical and translational research through global Phase III studies.
  • Before that, he was Senior Director, Clinical Development, at Neon Therapeutics, which was acquired by BioNTech.

Lundquist Principal Investigator Dr. Michael Yeaman Awarded $11.5 Million NIAID/HHS Grant for Innovative Research To Understand and Solve Persistent Bloodstream Infections

Retrieved on: 
Tuesday, August 15, 2023
Vaccine, Infection, DNA, Duke University Hospital, Centers for Disease Control and Prevention, Genetics, TLI, Epigenomics, Public, National Institute of Allergy and Infectious Diseases, MRSA, Immunity, Biomedical Research, Hope, Research, Antimalarial medication, Staphylococcus, Doctor of Philosophy, Bangladesh Technical Education Board, CDC, Harbor–UCLA Medical Center, Molecular medicine, Principal investigator, Division, Risk, Immune system, Nightfall and Other Stories, Biological engineering, NIAID, Principal, UCLA, United States Department of Health and Human Services, NIH, Bloodstream infections, Pharmaceutical industry, Health, Medicine, U19

In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.

Key Points: 
  • In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.
  • The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.
  • Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.
  • “We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman.

EQS-News: Epigenomics AG publishes financial results for the first six months 2023

Retrieved on: 
Thursday, August 10, 2023
Executive, CMS, Fairness, Epigenomics AG, Supervisory board, FSE, USD, Sale, Medicare, EUR, Federal Executive Boards, EBITDA, IDW, ECX, Supervision, R, FDA, German Institute for Economic Research, Raute (company), Security (finance), Pharmaceutical industry, Bank, Audit, Lithium, Epigenomics

Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.

Key Points: 
  • Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.
  • Ultimately, an agreement was reached with New Day Diagnostics LLC on July 24, 2023, to sell substantially all of Epigenomics' assets.
  • In terms of cash consumption, Epigenomics forecasts a range of EUR 7.0 million to EUR 9.0 million for the current full year 2023.
  • The interim statement for the first half of 2023 (unaudited) can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .